Provided by Tiger Trade Technology Pte. Ltd.

Collegium Pharmaceutical

34.50
-0.5000-1.43%
Post-market: 34.500.00000.00%16:10 EDT
Volume:413.50K
Turnover:14.31M
Market Cap:1.09B
PE:19.94
High:35.27
Open:35.15
Low:34.39
Close:35.00
52wk High:50.79
52wk Low:23.23
Shares:31.61M
Float Shares:28.09M
Volume Ratio:0.75
T/O Rate:1.47%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.73
EPS(LYR):1.73
ROE:23.70%
ROA:7.27%
PB:3.62
PE(LYR):19.94

Loading ...

Collegium Pharmaceutical Q4 Revenue USD 205.4 Million VS. Ibes Estimate USD 206.4 Million

THOMSON REUTERS
·
Feb 26

Collegium Pharmaceutical - Reaffirmed Full-Year 2026 Guidance

THOMSON REUTERS
·
Feb 26

Boston Legacy FC Announces Sensory Room Sponsorship with Collegium Pharmaceutical

GlobeNewswire
·
Feb 23

Earning Preview: Collegium Pharmaceutical this quarter’s revenue is expected to increase by 14.78%, and institutional views are predominantly bullish

Earnings Agent
·
Feb 19

Collegium Pharmaceutical price target raised to $58 from $55 at Truist

TIPRANKS
·
Feb 10

Truist Adjusts Price Target on Collegium Pharmaceutical to $58 From $55, Maintains Buy Rating

MT Newswires Live
·
Feb 10

Collegium Pharmaceutical management to meet with Truist

TIPRANKS
·
Feb 06

What Collegium Pharmaceutical (COLL)'s Revenue Surge and Low Valuation Means For Shareholders

Simply Wall St.
·
Feb 03

Collegium Pharmaceutical Showcases New Real-World Data on Jornay PM at APSARD 2026

Reuters
·
Jan 15

Does Collegium’s 2026 Revenue Guidance After Insider Sales Change The Bull Case For COLL?

Simply Wall St.
·
Jan 15

Collegium Pharmaceutical price target raised to $60 from $46 at H.C. Wainwright

TIPRANKS
·
Jan 09

Collegium Pharmaceutical Is Maintained at Buy by Needham

Dow Jones
·
Jan 09

Collegium Pharmaceutical (COLL) Receives a Buy from Barclays

TIPRANKS
·
Jan 09

Collegium Pharmaceutical: Strengthened 2026 Outlook, Balance Sheet Flexibility, and BD Upside Support Buy Rating and Higher Target

TIPRANKS
·
Jan 09

BRIEF-Collegium Pharmaceutical Outlook FY Revenue USD 805-825 Million

Reuters
·
Jan 08

Collegium Pharmaceutical Inc: on Track to Achieve Recently Increased Financial Guidance for 2025

THOMSON REUTERS
·
Jan 08

Press Release: Collegium Provides 2026 Financial Guidance and Business Update

Dow Jones
·
Jan 08

Truist Securities Adjusts Price Target on Collegium Pharmaceutical to $55 From $48, Maintains Buy Rating

MT Newswires Live
·
Jan 07

Press Release: Collegium Announces the Closing of $980 Million Syndicated Credit Facility

Dow Jones
·
Dec 30, 2025

Dyne Therapeutics Appoints Vikram Karnani to Board of Directors

Reuters
·
Dec 23, 2025